Evaluation of the abuse potential of AM281, a new synthetic cannabinoid CB1 receptor antagonist

European Journal of Pharmacology

Volumn 766, Issue , 2015, Pages 135-141

  Botanas, Chrislean Jun ^a   De La Peña, June Bryan ^a   Dela Pena, Irene Joy ^a   Tampus, Reinholdgher ^a   Kim, Hee Jin ^a   Yoon, Seong Shoon ^b   Seo, Joung Wook ^b   Jeong, Eun Ju ^b   Cheong, Jae Hoon ^a  

^a Sahmyook University   (South Korea)

^b Korea Institute of Toxicology   (South Korea)

Author keywords

Abuse potential; AM281; Cannabinoid antagonist; Conditioned place preference; Self administration

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; BRAIN FUNCTION; CONDITIONED PLACE PREFERENCE TEST; CONTROLLED STUDY; DRUG ABUSE; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG SCREENING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; SELF ADMINISTRATION TEST; TREATMENT RESPONSE; ADDICTION; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SELF ADMINISTRATION; INSTRUMENTAL CONDITIONING; SPRAGUE DAWLEY RAT;

ANIMALS; BEHAVIOR, ANIMAL; CANNABINOID RECEPTOR ANTAGONISTS; CONDITIONING, OPERANT; MALE; MORPHOLINES; PYRAZOLES; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS;

EID: 84944810492     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.10.004     Document Type: Article

References (48)

1. R. Alonso, B. Voutsinos, M. Fournier, C. Labie, R. Steinberg, J. Souilhac, G. Le Fur, and P. Soubrie Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D 2 function Neuroscience 91 1999 607 620
2. C.L. Baker, and J.J. McDougall The cannabinomimetic arachidonyl-2-chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints Br. J. Pharmacol. 142 2004 1361 1367
3. P.M. Beardsley Evaluation of taranabant (MK-0364) for its self-administration in rhesus monkeys and for its discriminative stimulus effects in rats Drug Dev. Res. 70 2009 577 584
4. P.M. Beardsley, M.E. Dance, R.L. Balster, and P. Munzar Evaluation of the reinforcing effects of the cannabinoid CB 1 receptor antagonist, SR141716, in rhesus monkeys Eur. J. Pharmacol. 435 2002 209 216
5. 1 receptor antagonists as potential pharmacotherapies for drug abuse disorders Int. Rev. Psychiatry 21 2009 134 142
6. I. Brown, M.G. Cascio, K.W. Wahle, R. Smoum, R. Mechoulam, R.A. Ross, R.G. Pertwee, and S.D. Heys Cannabinoid receptor-dependent and-independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and-negative prostate cancer cell lines Carcinogenesis 31 2010 1584 1591
7. 1) receptors in the establishment of place conditioning in rats Psychopharmacology 135 1998 324 332
8. J. Cheer, D. Kendall, and C. Marsden Cannabinoid receptors and reward in the rat: a conditioned place preference study Psychopharmacology 151 2000 25 30
9. 1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats Behav. Pharmacol. 13 2002 451 463
10. S. Comer, S. Lac, C. Wyvell, L. Curtis, and M. Carroll Food deprivation affects extinction and reinstatement of responding in rats Psychopharmacology 121 1995 150 157
11. 1 receptor leads to reinstatement of MDMA-induced conditioned place preference Pharmacol. Biochemi. Behav. 100 2011 33 39
12. J.B.I. de la Peña, I.J.I. dela Peña, H.L. Lee, I. dela Peña, C.Y. Shin, A.R. Sohn, and J.H. Cheong Pre-exposure to ethanol, but not to caffeine and nicotine, induced place preference and self-administration of the NMDA receptor antagonist-benzodiazepine combination, Zoletil® Pharmacol. Biochem. and Behav. 110 2013 231 237
13. J.B.I. de la Peña, H.C. Lee, C. Ike, T.S. Woo, S.Y. Yoon, H.L. Lee, J.S. Han, J.I. Lee, Y.J. Cho, and C.Y. Shin Rewarding and reinforcing effects of the NMDA receptor antagonist-benzodiazepine combination, zoletil®: difference between acute and repeated exposure Behav. Brain Res. 233 2012 434 442
14. 1 but not opioid receptors Neurosci. Lett. 226 1997 159 162
15. E. Fride, T. Bregman, and T.C. Kirkham Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood Exp. Biol. Med. 230 2005 225 234
16. 1 receptors in vivo J. Neurochem. 70 1998 417 423
17. S. Ghozland, H.W. Matthes, F. Simonin, D. Filliol, B.L. Kieffer, and R. Maldonado Motivational effects of cannabinoids are mediated by μ-opioid and κ-opioid receptors J. Neurosci. 22 2002 1146 1154
18. P. Gielow, P. Klinge, W. Knapp, and G. Berding Synthesis and preliminary biological evaluation of [123 I] Me 2 Pyr, a new potential ligand for imaging of central cannabinoid CB 1 receptors Appl. Radiat. Isot. 64 2006 763 768
19. A.N. Gifford, Y. Tang, S.J. Gatley, N.D. Volkow, R. Lan, and A. Makriyannis Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices Neurosci. Lett. 238 1997 84 86
20. 1-specific agents Behav. Pharmacol. 15 2004 299 304
21. D.M. Hutcheson, E.T. Tzavara, C. Smadja, E. Valjent, B.P. Roques, J. Hanoune, and R. Maldonado Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with Δ-9-tetrahydrocannabinol Br. J. Pharmacol. 125 1998 1567 1577
22. Z. Justinova, S.R. Goldberg, S.J. Heishman, and G. Tanda Self-administration of cannabinoids by experimental animals and human marijuana smokers Pharmacol. Biochem. Behav. 81 2005 285 299
23. Y. Kadoi, S. Saito, and F. Goto A cannabinoid antagonist, Am 281, reduces mortality rate and neurological dysfunction after cecal ligation and puncture in rats.: 184 Crit. Care Med. 34 2006 A47
24. K. Kitaichi, Y. Noda, T. Hasegawa, H. Furukawa, and T. Nabeshima Acute phencyclidine induces aversion, but repeated phencyclidine induces preference in the place conditioning test in rats Eur. J. Pharmacol. 318 1996 7 9
25. G.F. Koob, and N.D. Volkow Neurocircuitry of addiction Neuropsychopharmacology 35 2010 217 238
26. 1 selective cannabinoid antagonist AM281: a potential human SPECT ligand AAPS PharmSci 1 1999 39 45
27. F. Li, Q. Fang, Y. Liu, M. Zhao, D. Li, J. Wang, and L. Lu Cannabinoid CB 1 receptor antagonist rimonabant attenuates reinstatement of ketamine conditioned place preference in rats Eur. J. Pharmacol. 589 2008 122 126
28. C.R. Lupica, and A.C. Riegel Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction Neuropharmacology 48 2005 1105 1116
29. R. Maldonado, and F.R. de Fonseca Cannabinoid addiction: behavioral models and neural correlates J. Neurosci. 22 2002 3326 3331
30. C. Manzanedo, M.A. Aguilar, M. Rodríguez-Arias, M. Navarro, and J. Miñarro Cannabinoid agonist-induced sensitisation to morphine place preference in mice Neuroreport 15 2004 1373 1377
31. M. Martellotta, G. Cossu, L. Fattore, G. Gessa, and W. Fratta Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice Neuroscience 85 1998 327 330
32. 1 antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction Br. J. Pharmacol. 132 2001 1809 1816
33. 1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine Behav. Pharmacol. 10 1999 429 432
34. T. Nabeshima, K. Kitaichi, and Y. Noda Functional Changes in Neuronal Systems Induced by Phencyclidine Administrationa Ann. N. Y. Acad. Sci. 801 1996 29 38
35. M. Navarro, M. Carrera, W. Fratta, O. Valverde, G. Cossu, L. Fattore, J. Chowen, R. Gomez, I. Del Arco, and M. Villanua Functional interaction between opioid and cannabinoid receptors in drug self-administration J. Neurosci. 21 2001 5344 5350
36. E.J. Nestler Is there a common molecular pathway for addiction? Nat. Neurosci. 8 2005 1445 1449
37. Y. Noda, and T. Nabeshima Involvement of Signal Transduction Cascade via Dopamine-D1 Receptors in Phencyclidine Dependence Ann. N. Y. Acad. Sci. 1025 2004 62 68
38. R.G. Pertwee Inverse agonism and neutral antagonism at cannabinoid CB 1 receptors Life Sci. 76 2005 1307 1324
39. Prus, A.J., James, J.R., Rosecrans, J.A., 2009. Conditioned place preference. Methods of Behavior Analysis in Neuroscience, vol. 2, pp. 59-76
40. M. Rabbani, G. Vaseghi, and V. Hajhashemi AM281, Cannabinoid Antagonist/Inverse agonist, ameliorates scopolamine-induced cognitive deficit Iran. J. Basic Med. Sci. 15 2012 1106
41. 1 receptors Prog. Neuro-Psychopharmacol. Biol. Psychiatry 47 2013 77 84
42. M. Rutkowska, J. Jamontt, and H. Gliniak Effects of cannabinoids on the anxiety-like response in mice Pharmacol. Rep. 58 2006 200
43. M.C. Sañudo-Peña, K. Tsou, E.R. Delay, A.G. Hohman, M. Force, and J.M. Walker Endogenous cannabinoids as an aversive or counter-rewarding system in the rat Neurosci. Lett. 223 1997 125 128
44. M. Singh, A. Verty, I. McGregor, and P. Mallet A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine Brain Res. 1026 2004 244 253
45. E.T. Tzavara, K.W. Perry, D.E. Rodriguez, F.P. Bymaster, and G.G. Nomikos The cannabinoid CB 1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus Eur. J. Pharmacol. 426 2001 R3 R4
46. T.M. Tzschentke Review on CPP: measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade Addict. Biol. 12 2007 227 462
47. N.A. Werner, and J.E. Koch Effects of the cannabinoid antagonists AM281 and AM630 on deprivation-induced intake in Lewis rats Brain Res. 967 2003 290 292
48. J.M. Witkin, E.T. Tzavara, R.J. Davis, X. Li, and G.G. Nomikos A therapeutic role for cannabinoid CB 1 receptor antagonists in major depressive disorders Trends Pharmacol. Sci. 26 2005 609 617